Tradestie Institutional Equity Comparison Engine

EVMN vs OVID โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

OVID Overall Edge

OVID Captures Institutional Edge (2โ€“2 Pillars ยท 7โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Ovid Therapeutics Inc. Common Stock (OVID) driven by superior Valuation, Momentum & Technical while EVMN counters with relative strength in Growth & Margin, Options & Structure. Fundamentally, EVMN trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus OVID at 1.8x Forward P/E and -4693.7% operating margin (-88.3% YoY). In options structure, EVMN sits in SURGE (53rd %ile IV; Dealer Gamma Walls on Pro) against OVID sits in CONSOLIDATION (30th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner OVID
EVMN N/M vs OVID 1.8x Fwd P/E
Growth & Margin Winner EVMN
Op Margin 0.0% vs -4693.7% ยท YoY +0.0% vs -88.3%
Momentum & Technical Winner OVID
1Y -61.0% vs +100.0% ยท 52W Pos 8% vs 63%
Options & Structure Winner EVMN
SURGE (53rd %ile IV) vs CONSOLIDATION (30th %ile IV)
EVMN US Equity
Evommune, Inc.
Pharmaceutical Preparations
$7.10
-6.95% 1D
Market Cap $315.5M
1M Return +37.33%
1Y Return -61.03%
Forward P/E N/M
Unified AI Score
30.0 / 100 SELL
Tech 50.0 Fund 35.0 Flow 69.0 Mom 44.0
OVID NASDAQ
Ovid Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$2.40
-5.51% 1D
Market Cap $479.4M
1M Return +11.63%
1Y Return +100.0%
Forward P/E 1.8x
Unified AI Score
43.5 / 100 HOLD
Tech 15.0 Fund 42.0 Flow 67.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: EVMN -61.03% OVID +100.0% Spread: +161.03 pp (OVID Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period EVMN Revenue OVID Revenue EVMN Op. Margin OVID Op. Margin Margin Edge
FY2020 N/A $10M N/A -645.4% OVID
FY2021 N/A $210M N/A 59.6% OVID
FY2022 N/A $0M N/A -3696.4% OVID
FY2023 N/A $0M N/A -15122.7% OVID
FY2024 $10M $0M -1000.2% -10933.7% EVMN
FY2025 $10M $10M -623.6% -585.2% OVID

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: EVMN (2) vs OVID (7)
Institutional Metric EVMN OVID Criterion Row Winner
Market Capitalization Scale $315.5M $479.4M Larger Scale OVID
Trailing P/E Ratio Valuation N/M 1.8x Lower Multiple OVID
Forward P/E Ratio Valuation N/M 1.8x Lower Multiple OVID
Revenue Growth (YoY) Growth +0.0% -88.3% Higher Growth EVMN
Operating Margin (TTM) Profitability 0.0% -4693.7% Higher Margin EVMN
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -69.5% -35.4% Higher ROE OVID
52-Week Range Position Momentum 8% ($5โ€“$33) 63% ($1โ€“$3) Stronger Trend OVID
Beta / 30D Volatility Risk Regime 1.05ฮฒ ยท 118% Vol 0.98ฮฒ ยท 97% Vol Lower Realized Risk OVID
Unified Institutional Score Composite Signal 30.0 / 100 (SELL) 43.5 / 100 (HOLD) Higher Composite OVID

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full EVMN vs OVID Buy Guide
EVMN SURGE
5d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 53rd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live EVMN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
OVID CONSOLIDATION
150d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 30th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live OVID Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither EVMN nor OVID registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.